Capitolis Liquid Global Markets’s Taysha Gene Therapies TSHA Stock Holding History

Capitolis Liquid Global Markets’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$11.2M	Buy	+2,300,000	New	+$13.3M	0.05%	186

Other funds holding TSHA

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 38.25% 1-Year Est. Return

Quantum Private Wealth Tampa, Florida $391M AUM 50.76% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Capitolis Liquid Global Markets's TSHA Position: Q3 2026 in Review

Capitolis Liquid Global Markets opened a new position in Taysha Gene Therapies (TSHA) in Q3 2026: 2,300,000 shares worth $11.2M. The stake represents 0.05% of the portfolio and ranks #186 among its holdings.

105 funds tracked by Wall St. Rank hold TSHA as of Q3 2026.

Capitolis Liquid Global Markets held 2,300,000 shares of Taysha Gene Therapies worth $11.2M as of Q3 2026.
Taysha Gene Therapies was a new Capitolis Liquid Global Markets position in Q3 2026.
Taysha Gene Therapies made up 0.05% of Capitolis Liquid Global Markets's portfolio in Q3 2026, its #186 holding.
105 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q3 2026.

Based on Capitolis Liquid Global Markets's 13F filing for Q3 2026, filed 12 Nov 2026.